Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

BioLineRx Ltd (BLRX)

NASDAQ
Symbol
Exchange
Currency
BLRXNASDAQUSD
BLRXTel AvivILS
Currency in USD
Disclaimer
0.656
+0.016(+2.56%)
Closed
After Hours
0.660+0.004(+0.61%)

BLRX Comments

+300% on Monday
The market will be closed tomorrow😉
PDUFA target action date set for September 9, 2023
BioLineRx Announces Submission of New Drug Application (NDA) to FDA for Motixafortide in Stem Cell Mobilization
They get fda fast track!!!
Now it looks like my lucky ticket to the moon 🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝🌝
Get ready for the plane's take-off.
I will not be a surprise, if this stock goes with 3 digit figures in the long run. lots of potential is hidden and should bustout anytime.
journey begins...
https://www.tipranks.com/stocks/blrx/forecast
Do they really had good results ?The stock behavior say otherwise
they will file for approval early next year, hopefully this will help it pick up again
BioLine RX rockets on heavy volume after 'strikingly positive' trial data on cancer treatment
Any chance that the result was overrated? How is us market reacting to the results?
Not overrated
If so this can hit $30 with ease
Only me?
What r the reactions to the news? On US?
D*mn! Site frozen
Any news??
BLRX should be back in force from May 20th...keep holding, keep accommodating and keep patience. Price below 3 will be a dream later! Research and approvals is a long-term process...
Samir you're breaking the car
BIOLINERX LTD.   NOTICE OF EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS ON APRIL 5, 2021  Whtat are you toughts?
Going long, already up quite a bit and it is a lonely green island in a sea of red today.
i was says the same before this big pull back, do you have any ideas news of the highest pt soon?
Hello Neta, what do you think about BLRX? i am still holding long and strong
Upcoming Significant Expected MilestonesTop-line results from the Phase 3 GENESIS trial in SCM in early Q2 2021.Initial results from Part 2 of the Phase 1/2a trial of AGI-134 in solid tumors in the second half of 2021.Pre-NDA meeting with the FDA for SCM in the second half of 2021NDA submission for SCM in the first half of 2022
Announced positive results from an interim analysis of its GENESIS Phase 3 trial of motixafortide in stem-cell mobilization (SCM). The interim analysis found statistically significant evidence for the primary endpoint favoring treatment with motixafortide. Based on a recommendation from the independent Data Monitoring Committee (DMC), enrollment was ceased early at 122 patients (instead of 177 originally planned), and top-line data, including full primary and secondary efficacy endpoints, is anticipated in early second quarter of 2021. In parallel, the Company is proceeding with all activities in support of an NDA submission in this indication anticipated in the first half of 2022, including a pre-NDA meeting with the FDA planned for the second half of 2021.
Any news on BLRX?
No :( patience but slowly i lost the believe on this stock!
 thank you Neta, I think we have to keep the faith, I am holding long and strong BLRX or we made a mistake to not sell it at 4.25 weeks ago
Green island in a sea of red today.
Looks like an opportunity
BLRX, EXPECT VERY GOOD NEWS TO ME FDA PHASE 3 OF MEDICATION, SO TIPRANKSThe analyst added, “We believe results from the Phase 3 GENESIS trial could spur the majority of transplant physicians to choose BL-8040 over Mozobil to combine with G-CSF if the drug is approved. Upside to our thesis includes BL-8040 for use in other auto-HSCTs, allo-HSCTs, AML, and solid tumors. The company boasts a catalyst-rich, deep oncology pipeline that has attracted collaborations with Novartis, Merck, and Genentech. ”
Thank you to share Neta, I am holding BLRX long and strong
This will surely be up soon again. Small bumps are expected. Then it will ramp again, and if more positive news hits then it will sharply ascend.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.